fig5

Figure 5. LPS-conditioned medium activated PI3K/AKT/Cas-9 signaling and prophylactic administration of Vatalanib improved the prognosis of the pneumonia mice. (A) KEGG analysis based on cytokine array; (B) Western blot of PI3K/AKT signaling of HCC cells cultured in the Control-conditioned and LPS-conditioned medium; (C) Activation of the PI3K/AKT signaling was abrogated with PI3K inhibitor LY294002 or AKT inhibitor MK-2206 2HCl; Changes in apoptosis of Huh-7 (D) and SK-Hep-1 (E) was abrogated by Vatalanib; (F) Cumulative survival of the pneumonia mice administered with PBS or Vatalanib (P < 0.05); CD31 staining of the metastatic nodules of the pneumonia mice administered with PBS (G) or Vatalanib (H).